Leap Therapeutics Inc LPTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LPTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.00
- Day Range
- $2.95–3.20
- 52-Week Range
- $1.24–10.20
- Bid/Ask
- $2.95 / $3.17
- Market Cap
- $76.30 Mil
- Volume/Avg
- 151,110 / 335,888
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- < 0.01%
Company Profile
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 54
- Website
- https://www.leaptx.com
Valuation
|
Metric
|
LPTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.45 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LPTX
|
|---|---|
Quick Ratio | 5.63 |
Current Ratio | 5.64 |
Interest Coverage | — |
Quick Ratio
LPTX
Profitability
|
Metric
|
LPTX
|
|---|---|
Return on Assets (Normalized) | −88.99% |
Return on Equity (Normalized) | −125.72% |
Return on Invested Capital (Normalized) | −131.33% |
Return on Assets
LPTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gcsmkybbqj | Lbmt | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zkzpltxn | Hylsrcc | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kkswmrnx | Mhjwfw | $98.6 Bil | |
MRNA
| Moderna Inc | Rslxsrgsr | Qxkb | $41.0 Bil | |
ARGX
| argenx SE ADR | Zjjbxtm | Pgrmz | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Nxbptpb | Xtj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tbgzygm | Rdmhfz | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Znwbxyjg | Jgfbyj | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Njhmqnnbl | Trlydbj | $12.6 Bil | |
INCY
| Incyte Corp | Dhyfptpk | Rkfhmz | $12.0 Bil |